Fundación MEDINA

21/04/2026

Developing a Miniaturized Alternative to ELISA for Antigen-Antibody Validation.

Validating antigen-antibody interactions is a cornerstone of R&D, yet traditional methods like ELISA can often become bottlenecks due to their cost, time requirements, and lack of scalability.

In collaboration with Rekom Biotech, we aimed at overcoming these limitations and developed a quick, cost-effective, and miniaturized method that surpasses traditional ELISA performance. By leveraging our HTS infrastructure, we successfully transitioned the R&D workflow into a more efficient analytical approach.

👉 Read below about the experience of Hadyn Duncan, Cell Line Manager and Senior R&D Scientist at Rekom Biotech

Fundación MEDINA

16/04/2026

Validating Target-Engagement at an Industrial Scale.

In the development of therapeutic inhibitors, demonstrating Target Engagement is essential to prove that a molecule binds to its intended target in a biological environment. However, scaling these assays for industrial applications requires a high degree of robustness and reproducibility.

Through a strategic co-development with Promega, we developed an innovative High-Throughput Screening workflow using Target Engagement technology, designed to identify potent and selective inflammasome inhibitors. This collaboration also led to a peer-reviewed publication, validating the scientific excellence and industrial readiness of the methodology.

👉 Read below about the experience of Matthew Robers, Associate Director, R&D at Promega.
Corporation MEDINA

14/04/2026

Fundación MEDINA is part of the -VRE project, aimed at developing new therapies against infections caused by vancomycin-resistant Enterococcus faecium.

The project is led by the biotechnology company Telum Therapeutics and involves the participation of the Blas Cabrera Institute of Physical Chemistry (CSIC) and the Seville Institute of Biomedicine (IBiS).

We are proud to bring our expertise in advanced analytical research to a project with such strong potential to improve patient outcomes.
Read the full piece here:

https://www.medinadiscovery.com/medina-participates-in-the-nova-vre-project-to-develop-new-therapies-to-combat-antibiotic-resistant-bacteria/

Stay tuned for updates! 🔬

IBiS Instituto de Biomedicina de Sevilla Instituto de Química Física Blas Cabrera (IQF-CSIC) Ministerio de Ciencia e Innovación y Universidades AGENCIA ESTATAL DE INVESTIGACIÓN

MEDINA participates in the NOVA-VRE project to develop new therapies to combat antibiotic-resistant bacteria. Granada, April 13, 2026 Fundación MEDINA is part of the NOVA-VRE consortium, an R&D project aimed at developing new therapies based on enzybiotics to combat infections caused by vancomycin-...

08/04/2026

Hit prioritization through orthogonal binding assays.

In drug discovery, identifying hits is only the beginning; the real challenge lies in prioritizing them correctly to eliminate false positives and ensure only the most promising candidates move forward.

At Fundación MEDINA, we integrate our expertise in Thermal Shift Assays and orthogonal binding assays to transform a discovery phase into a robust and reliable prioritization strategy.

👉 Read below about the experience of Mamatha B Nijaguna, Principal Investigator at Institute for Bioengineering of Catalonia (IBEC)
Universidad de Granada Junta de Andalucía MSD España

24/03/2026

From a conventional enzymatic assay to a high-throughput screening platform in weeks.

Transitioning an optimized in vitro assay from an academic setting to high-throughput screening requires more than just automation; it demands a fundamental redesign of the assay’s robustness.

At Fundación MEDINA, we are experts in developing automated and miniaturized assays starting from your proof-of-concept. We transform your experimental assay into a fully operational, high-throughput platform.

👉 Read below about the experience of Prof. Ruben Martinez-Buey at the University of Salamanca

Universidad de Salamanca Universidad de Granada Junta de Andalucía MSD España

18/03/2026

The evaluation of metabolic stability is a standard procedure in early drug discovery. However, relying solely on disappearance rates often overlooks the formation of active or reactive metabolites. These unidentified species can cause toxicity, leading to late-stage dropout.

At Fundación MEDINA, we offer a comprehensive approach to Metabolite Profiling. Our objective is to provide the chemical evidence necessary to rule out safety risks before moving to regulatory phases.

Analytical Capabilities:

🟢 High-Resolution LC-HRMS: We utilize high-resolution accurate mass technology for the unambiguous identification and quantification of metabolites from both in vitro and in vivo matrices.
🟢 Integrated ADME-Tox: Our service combines systematic workflows with in-depth scientific interpretation of every metabolite profile.

👉For detailed specifications on our LC-MS solutions or to discuss a custom ADME-Tox protocol, please contact our scientific team.


Universidad de Granada Junta de Andalucía MSD España

16/03/2026

🎉 Fundación MEDINA celebra con su paso a la siguiente fase de la Capital Europea de la Cultura 2031.
Desde Fundación MEDINA, entidad que lleva Granada en su ADN, nos sumamos a esta candidatura hace tiempo porque creemos profundamente que la ciencia también es cultura.
Este primer sí es un reconocimiento al trabajo, a la ilusión y al proyecto colectivo que hay detrás. Pero el camino continúa, y nosotros seguimos ahí, apoyando cada paso.

💪 Vamos, Granada. El mejor capítulo aún está por escribirse.
Granada 2031 UNESCO CSIC New Ground Research Fundación Unicaja Diputación de Granada Ayuntamiento de Granada Cámara Comercio Granada Junta de Andalucía MSD España

05/03/2026

Entering regulatory phases with the wrong candidate is a costly mistake. The key to efficiency in Drug Discovery lies in the preliminary phase: Non-GLP Preclinical Research.

At Fundación MEDINA, we offer a flexible and cost-effective approach to Non-GLP Preclinical Studies. Our goal isn't just to generate data, but to generate exploratory knowledge that allows you to refine hypotheses and select the best drug candidate for optimization.

Why choose our Non-Regulatory Preclinical approach?

✅ Smart De-risking: Anticipate toxic/genotoxic effects and potential interactions early, reducing the probability of failure in later stages.

✅ Cost-Efficiency: Because non-GLP studies are more affordable, you can analyze multiple candidates simultaneously to identify the winner based on robust Go/No-Go criteria.

✅ Ethical Innovation: We prioritize in vitro over in vivo models following the 3Rs rule (Replacement, Reduction, Refinement), aligned with RD 1386/2018.

We offer the infrastructure of a large center with the accessibility of a dedicated service provider.
👇 ready to de-risk your candidate? Contact our team for a customized proposal.
https://www.medinadiscovery.com/
Universidad de Granada Junta de Andalucía MSD España

27/02/2026

Ayer en Fundación MEDINA recibimos la visita de los alumnos del Máster en Biología Agraria y Acuicultura de la Universidad de Granada, acompañados por el profesor Alberto Bago, Estación Experimental del Zaidín-CSIC.

Durante la visita, los estudiantes tuvieron la oportunidad de conocer como los avances en biotecnología microbiana que se desarrollan en la Fundación son cruciales para una Agricultura más Sostenible.

🔬 La visita estuvo llena de momentos inspiradores, donde los alumnos pudieron interactuar con nuestros investigadores, plantear preguntas y explorar posibles colaboraciones, ampliando sus horizontes académicos y brindándoles una valiosa perspectiva sobre el impacto real de la investigación e innovación científica en nuestra sociedad.

Universidad de Granada MSD España Junta de Andalucía hashtag

27/02/2026

Tomorrow is Rare Disease Day

While individual rare diseases affect a small number of people, their collective impact is a global health challenge. When each individual disease might only have a few cases around the world, tools like iPSC technology and gene editing become fundamental to generate cell-based models that help understanding the mechanisms underlying rare diseases.

At Fundación MEDINA, we use iPSC-based gene modeling to seek therapeutic options for rare diseases.

Research into rare diseases is not just about the few; it is also about advancing our fundamental understanding of human biology through cutting-edge science.
Universidad de Granada Junta de Andalucía MSD España

26/02/2026

¡En Fundación MEDINA estamos de enhorabuena!
Felices y orgullosos de nuestra investigadora predoctoral, Inmaculada Iáñez García, que ha recibido el premio al mejor TFM de Bioinformática en el celebrado durante las X Jornadas de Bioinformática de la de Granada (UGR) y esponsorizado por Revvity.
Este trabajo combina análisis de imagen de alto contenido con IA para evaluar el efecto de la quimioterapia en modelos 3D de cáncer de mama. Este reconocimiento pone en valor el impacto y la calidad científica de nuestros proyectos y de las nuevas generaciones de investigadores que se están formando en MEDINA.
¡Enhorabuena Inma!
Facultad de Ciencias de la Universidad de Granada Universidad de Granada MSD España Junta de Andalucía

17/02/2026

🚀 New Article Published! Unlocking the Power of Non GLP Preclinical Studies in Drug Discovery

Before a molecule becomes a drug candidate, it must survive one of the most challenging stages in R&D: preclinical evaluation. And this is where non GLP preclinical studies become true game changers.

In our latest article in Laboratory Animals journal, we highlight how early ADME tox studies—flexible, fast, and cost effective—empower teams to:

✨ Screen more candidates in less time
✨ Identify risks before they become expensive failures
✨ Make smarter go/no go decisions
✨ Select the strongest lead with confidence
✨ Reduce animal use by prioritizing in vitro models

These exploratory studies provide a competitive edge, helping organizations optimize resources while increasing the likelihood of success in later development phases.
Backed by insights from the Preclinical Area at Fundación MEDINA, the article also showcases companies offering ready to use models and on demand assays to accelerate discovery.
If your work touches early drug development, pharmacology, biotech innovation, or strategic R&D decisions… this is a must read.

https://www.medinadiscovery.com/wp-content/uploads/2026/02/Preclinical-Studies-and-GoNo-Go-Decision-Criteria-in-Early-Drug-Development.pdf

👉 Elevate your pipeline. Reduce risk. Accelerate innovation.

-tox SECAL, Sociedad Española para las Ciencias del Animal de Laboratorio Confederación de Sociedades Científicas de España (COSCE) Universidad de Granada MSD España Junta de Andalucía